(Abstracted from Gynecol Oncol 2024;181:170–178 Identification of germline and somatic pathogenic variants as well as homologous recombination deficiency (HRD) can contribute to the prediction of treatment response, prognostic outcome, and suitability for targeted agents. Germline genetic testing can also serve to inform risk for other malignancies and prompt risk management for at-risk relatives.
No takes yet. Share an insight, caveat, or question.
Gressel et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: